Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $128.7 million.

  • Avidity Biosciences' Shares Outstanding (Weighted Average) rose 17.17% to $128.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $128.7 million, marking a year-over-year increase of 17.17%. This contributed to the annual value of $119.3 million for FY2024, which is 61.01% up from last year.
  • Per Avidity Biosciences' latest filing, its Shares Outstanding (Weighted Average) stood at $128.7 million for Q3 2025, which was up 6.73% from $120.5 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Shares Outstanding (Weighted Average) registered a high of $128.7 million during Q3 2025, and its lowest value of $37.6 million during Q1 2021.
  • Over the past 3 years, Avidity Biosciences' median Shares Outstanding (Weighted Average) value was $95.6 million (recorded in 2024), while the average stood at $96.7 million.
  • Data for Avidity Biosciences' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 61.01% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Avidity Biosciences' Shares Outstanding (Weighted Average) stood at $46.9 million in 2021, then increased by 16.13% to $54.5 million in 2022, then surged by 36.06% to $74.1 million in 2023, then surged by 61.01% to $119.3 million in 2024, then increased by 17.17% to $128.7 million in 2025.
  • Its last three reported values are $128.7 million in Q3 2025, $120.5 million for Q2 2025, and $120.2 million during Q1 2025.